Waldenström's macroglobulinemia pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Waldenström's macroglobulinemia}} | {{Waldenström's macroglobulinemia}} | ||
{{CMG}} | {{CMG}} {{AE}}{{MGS}} | ||
==Overview== | ==Overview== | ||
== Pathogenesis == | == Pathogenesis == | ||
Revision as of 16:20, 3 November 2015
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia pathophysiology |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
Overview
Pathogenesis
It is due to the effects of the IgM paraprotein, which may cause autoimmune phenomenon or cryoglobulinemia. Other symptoms of WM are due to the hyperviscosity syndrome, which is present in 6-20% of patients.This is attributed to the IgM monoclonal protein increasing the viscosity of the blood.